Valeant Pharmaceuticals International, Inc. (VRX) Earns Hold Rating from Deutsche Bank AG

Deutsche Bank AG restated their hold rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research report sent to investors on Wednesday. The firm currently has a $19.00 price target on the specialty pharmaceutical company’s stock.

Several other analysts have also commented on VRX. Vetr upgraded Valeant Pharmaceuticals International from a buy rating to a strong-buy rating and set a $14.26 price objective for the company in a report on Thursday, October 19th. Zacks Investment Research lowered Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a report on Thursday, July 13th. ValuEngine lowered Valeant Pharmaceuticals International from a buy rating to a hold rating in a report on Friday, September 1st. Royal Bank Of Canada decreased their price objective on Valeant Pharmaceuticals International from $21.00 to $18.00 and set a sector perform rating for the company in a report on Friday, October 20th. Finally, Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a report on Sunday, July 30th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Valeant Pharmaceuticals International currently has an average rating of Hold and a consensus price target of $17.17.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at $15.38 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 4.84. The firm has a market capitalization of $5,350.89, a price-to-earnings ratio of 2.50, a price-to-earnings-growth ratio of 0.43 and a beta of -0.40. Valeant Pharmaceuticals International has a twelve month low of $8.31 and a twelve month high of $18.71.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a return on equity of 51.56% and a net margin of 15.35%. Valeant Pharmaceuticals International’s revenue was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.88) earnings per share. equities analysts forecast that Valeant Pharmaceuticals International will post 3.74 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Earns Hold Rating from Deutsche Bank AG” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/11/11/valeant-pharmaceuticals-international-inc-vrx-earns-hold-rating-from-deutsche-bank-ag.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 10,000 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the transaction, the director now directly owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 5.87% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of VRX. Ameriprise Financial Inc. grew its position in shares of Valeant Pharmaceuticals International by 31.3% during the 1st quarter. Ameriprise Financial Inc. now owns 44,149 shares of the specialty pharmaceutical company’s stock valued at $487,000 after acquiring an additional 10,534 shares during the period. Alliancebernstein L.P. grew its position in shares of Valeant Pharmaceuticals International by 49.3% during the 1st quarter. Alliancebernstein L.P. now owns 39,664 shares of the specialty pharmaceutical company’s stock valued at $437,000 after acquiring an additional 13,092 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Valeant Pharmaceuticals International by 33.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 2,763 shares during the period. Vanguard Group Inc. grew its position in shares of Valeant Pharmaceuticals International by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock valued at $76,990,000 after acquiring an additional 621,618 shares during the period. Finally, Paloma Partners Management Co grew its position in shares of Valeant Pharmaceuticals International by 12.0% during the 1st quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after acquiring an additional 2,996 shares during the period. Hedge funds and other institutional investors own 49.74% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply